bosentan anhydrous has been researched along with Bowel Diseases, Inflammatory in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anthoni, C; Krieglstein, CF; Laukötter, MG; Mennigen, RB; Rijcken, EJ; Schürmann, G; Senninger, N; Spiegel, HU | 1 |
1 other study(ies) available for bosentan anhydrous and Bowel Diseases, Inflammatory
Article | Year |
---|---|
Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bosentan; Cell Adhesion; Disease Models, Animal; Endothelin Receptor Antagonists; Female; Inflammatory Bowel Diseases; Leukocytes; Mice; Mice, Inbred BALB C; Severity of Illness Index; Sulfonamides | 2006 |